Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $31.8KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations | Aug 03 '26 | Sale | $1.98 | 275 | $544 | 504,819 | Aug 05 04:08 PM |
| Russotti Gregory | See Remarks | Jun 12 '26 | Sale | $2.23 | 2,584 | $5,767 | 512,319 | Jun 15 07:57 PM |
| Carr Douglas | SVP Finance & Operations | Jun 12 '26 | Sale | $2.23 | 1,654 | $3,692 | 505,094 | Jun 15 07:56 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.